The U.S. Food and Drug Administration has allowed marketing of OraSure Technologies’ OraQuick Ebola Rapid Antigen, a rapid diagnostic test to detect Ebola virus antigens in human blood. This test is the first rapid diagnostic test that the FDA has allowed to be marketed in the U.S. for the Ebola Virus Disease, and provides another important tool in the effort to fight Ebola. More